<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vindesine (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vindesine (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Vindesine (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F234309"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Antimicrotubular;</li>
<li>
                        Antineoplastic Agent, Vinca Alkaloid</li></ul></div>
<div class="block doa drugH1Div" id="F234282"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Patients should be on a prophylactic bowel regimen to prevent obstipation.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a881e1b5-4635-4167-8c83-7c4811057163">Adult T-cell leukemia/lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adult T-cell leukemia/lymphoma (off-label use):</b>
<b>IV:</b> 2.4 mg/m<sup>2</sup> on day 15 (as part of the VCAP-AMP-VECP multi-agent chemotherapy regimen) (Tsukasaki 2007).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70f72d8d-3f95-478a-a281-8d0e7521cd98">Breast cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, advanced:</b>
<b>IV:</b> Initial: 3 mg/m<sup>2</sup>; if no toxicity and granulocyte count is acceptable (avoid sustained granulocyte counts &lt;2,500/mm<sup>3</sup>), may increase dose in 0.5 mg/m<sup>2</sup> increments at weekly intervals (do not increase dose if granulocyte count &lt;1,500/mm<sup>3</sup>, platelet count &lt;100,000/mm<sup>3</sup>, or if acute abdominal pain is present). Usual range: 3 to 4 mg/m<sup>2</sup>; maximum dose/week: 4 mg/m<sup>2</sup>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e83a9ca3-b3aa-43a7-87a1-d31422513194">Chronic myeloid leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic myeloid leukemia (blast crisis):</b>
<b>IV:</b> Initial: 3 mg/m<sup>2</sup>; if no toxicity and granulocyte count is acceptable (avoid sustained granulocyte counts &lt;2,500/mm<sup>3</sup>), may increase dose in 0.5 mg/m<sup>2</sup> increments at weekly intervals (do not increase dose if granulocyte count &lt;1,500/mm<sup>3</sup>, platelet count &lt;100,000/mm<sup>3</sup>, or if acute abdominal pain is present). Usual range: 3 to 4 mg/m<sup>2</sup>; maximum dose/week: 4 mg/m<sup>2</sup>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c25d37b5-e8ac-42f8-909f-836b4c603745">Melanoma, malignant, unresponsive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, malignant, unresponsive:</b>
<b>IV:</b> Initial: 3 mg/m<sup>2</sup>; if no toxicity and granulocyte count is acceptable (avoid sustained granulocyte counts &lt;2,500/mm<sup>3</sup>), may increase dose in 0.5 mg/m<sup>2</sup> increments at weekly intervals (do not increase dose if granulocyte count &lt;1,500/mm<sup>3</sup>, platelet count &lt;100,000/mm<sup>3</sup>, or if acute abdominal pain is present). Usual range: 3 to 4 mg/m<sup>2</sup>; maximum dose/week: 4 mg/m<sup>2</sup>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="372da856-af0f-483e-afd5-b0946fd3c185">Non-Hodgkin lymphoma, diffuse large B-cell</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphoma, diffuse large B-cell (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">≤59 years of age: <b>IV:</b> 2 mg/m<sup>2</sup> on days 1 and 5 every 2 weeks (in combination with doxorubicin, cyclophosphamide, bleomycin, prednisone, and rituximab [R-ACVBP regimen]) for 4 cycles (with growth factor support), followed by sequential consolidation therapy (Molina 2014; Recher 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;61 years of age: <b>IV:</b> 2 mg/m<sup>2</sup> on days 1 and 5 every 2 weeks (in combination with doxorubicin, cyclophosphamide, bleomycin, and prednisone [ACVBP regimen]) for 3 cycles, followed by sequential consolidation therapy (Reyes 2005).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991921"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989136"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Dosage reductions may be necessary for significant hepatic or biliary impairment, however the manufacturer’s labeling does not provide specific adjustment recommendations.</p></div>
<div class="block doo drugH1Div" id="F20344293"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology </i>
<i>guidelines</i>
<i> for appropriate systemic therapy dosing in adults with cancer </i>
<i>with a BMI ≥30 kg/m<sup>2</sup></i>
<i>:</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (ASCO [Griggs 2021]).</p></div>
<div class="block dot drugH1Div" id="F45040078"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Gastrointestinal toxicity (acute abdominal pain):</i> Withhold dose. After treatment is resumed, do not increase dose above the dose where acute abdominal pain occurred.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Neurotoxicity:</i> May require dose reduction or temporary discontinuation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Pulmonary toxicity (progressive dyspnea requiring chronic therapy):</i> Permanently discontinue.</p></div>
<div class="block doe drugH1Div" id="F3062226"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F45040077"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d227b1fb-94e1-4e1c-bddd-a4472126e01f">Acute lymphoblastic leukemia, resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia, resistant:</b> Pediatric:<b> IV:</b> Initial: 4 mg/m<sup>2</sup>; if no toxicity and granulocyte count is acceptable (avoid sustained granulocyte counts &lt;2,500/mm<sup>3</sup>), may increase dose in 0.5 mg/m<sup>2</sup> increments at weekly intervals (do not increase dose if granulocyte count &lt;1,500/mm<sup>3</sup>, platelet count &lt;100,000/mm<sup>3</sup>, or if acute abdominal pain is present). Usual range: 4 to 5 mg/m<sup>2</sup>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity: </b>Pediatric:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gastrointestinal toxicity (acute abdominal pain):</i> Withhold dose. After treatment is resumed, do not increase dose above the dose where acute abdominal pain occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neurotoxicity:</i> May require dose reduction or temporary discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary toxicity (progressive dyspnea requiring chronic therapy):</i> Permanently discontinue.</p></div>
<div class="block dorp drugH1Div" id="F51193518"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51193519"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Dosage reductions may be necessary for significant hepatic or biliary impairment, however the manufacturer’s labeling does not provide specific adjustment recommendations.</p></div>
<div class="block adr drugH1Div" id="F234263"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Chills, convulsions, decreased deep tendon reflex, depression, headache, malaise, neurotoxicity, peripheral neuritis, tingling sensation of hands or feet</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Alopecia, cellulitis (with extravasation), localized vesiculation mouth, maculopapular rash</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dyspepsia, dysphagia, intestinal obstruction, nausea, paralytic ileus, perforated duodenal ulcer, stomatitis, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Granulocytopenia (nadir: 3 to 5 days; recovery: 7 to 10 days), mild anemia, thrombocythemia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Injection site reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Foot-drop, jaw pain, musculoskeletal pain, weakness</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Bronchospasm, dyspnea</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F234271"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to vindesine sulphate or any component of the formulation; intrathecal administration (fatal); demyelinating form of Charcot-Marie-Tooth syndrome; severe granulocytopenia (&lt;1,500/mm<sup>3</sup>) or severe thrombocytopenia; severe bacterial infection.</p></div>
<div class="block war drugH1Div" id="F234261"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Granulocytopenia is the dose-limiting toxicity; the nadir is generally 3 to 5 days after administration and recovery is rapid and usually complete within 7 to 10 days after the vindesine dose. Thrombocytopenia may occur if administered more frequently than once weekly, although platelets are usually unaffected or may increase when vindesine is administered weekly; thrombocytopenia is more likely when platelets are already low prior to treatment. Mild anemia may occur (rare).</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vindesine is a vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation. Extravasation may cause significant irritation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal effects: Nausea, vomiting, constipation, ileus, stomatitis, diarrhea, and/or abdominal pain may occur. Vindesine may cause acute abdominal pain; paralytic ileus may be a risk if further doses are administered. Patients should be on a prophylactic bowel regimen to prevent obstipation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurotoxicity: Neurotoxicity (eg, paresthesias, jaw pain, loss of deep tendon reflexes, foot drop, headache, convulsions) may occur; may require dose reduction. Use with caution in patients with preexisting neuromuscular disease; neurotoxicity may be additive. Neurotoxicity associated with vindesine may typically be less severe/progressive than that seen with other vinca alkaloids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory effects: Acute shortness of breath and severe bronchospasm have been reported with vinca alkaloids, usually when used in combination with mitomycin (may be severe in patients with preexisting pulmonary toxicity). Onset may be several minutes to hours after vinca administration and up to 2 weeks after mitomycin. Progressive dyspnea may occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hazardous agent: Avoid eye contamination; severe irritation or corneal ulceration may occur. If eye exposure occurs, wash eye immediately and thoroughly with water or saline.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• For IV use only: <b>For IV use only. Administration by other routes may be fatal.</b> To prevent administration errors, the World Health Organization strongly recommends dispensing vinca alkaloids diluted in a minibag (WHO 2007), <b>if not dispensed in a minibag, affix an auxiliary label stating “For intravenous use only - fatal if given by other routes” and also place in an overwrap labeled “Do not remove covering until moment of injection.”</b> Vindesine should be administered by individuals experienced in administering vinca alkaloids. Vinca alkaloids should <b>NOT</b> be prepared during the preparation of any intrathecal medications. After preparation, keep vindesine in a location <b>away</b> from the separate storage location recommended for intrathecal medications. Vindesine should <b>NOT</b> be delivered to the patient at the same time with any medications intended for central nervous system administration (ASCO/ONS [Neuss 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Radiation therapy recipients: If radiation therapy is through portals that include the liver, delay vindesine until after completion of radiation therapy.</p></div>
<div class="block prod-avail drugH1Div" id="F45040080"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block foc drugH1Div" id="F234267"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Solution Reconstituted, Injection, as sulphate: Eldisine: 5 mg [contains mannitol]</p></div>
<div class="block geq drugH1Div" id="F234258"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block adm drugH1Div" id="F234268"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> For IV administration only. <b>Fatal if given by other routes. </b></p>
<p style="text-indent:0em;margin-top:2em;">
<b>The World Health Organization strongly recommends dispensing vinca alkaloids in a minibag (NOT in a syringe).</b> Vindesine should <b>NOT</b> be delivered to the patient at the same time with any medications intended for CNS administration.</p>
<p style="text-indent:0em;margin-top:2em;">Administer IV over 1 to 3 minutes into a free-flowing IV line. The preferred vinca alkaloid administration is as a short 5- to 10-minute infusion in a 25 to 50 mL minibag (ISMP 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote; remove needle/cannula; apply dry warm compresses for 20 minutes 4 times a day for 1 to 2 days; elevate extremity (ESMO/EONS [Perez Fidalgo 2012]). Remaining portion of the vindesine dose should be infused through a separate vein.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hyaluronidase:</i> If needle/cannula still in place, administer 1 to 6 mL hyaluronidase (150 units/mL) into the existing IV line; the usual dose is 1 mL hyaluronidase for each 1 mL of extravasated drug (ESMO/EONS [Perez Fidalgo 2012]; Schulmeister 2011). If needle/cannula was removed, inject 1 to 6 mL (150 units/mL) SubQ in a clockwise manner using 1 mL for each 1 mL of drug extravasated (Schulmeister 2011) <b>or</b> administer 1 mL (150 units/mL) as 5 separate 0.2 mL injections (using a 25-gauge needle) SubQ into the extravasation site (Polovich 2009).</p></div>
<div class="block admp drugH1Div" id="F52614010"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> For IV administration only. <b>Fatal if given by other routes. </b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>The World Health Organization strongly recommends dispensing vinca alkaloids in a minibag (NOT in a syringe).</b> Vindesine should <b>NOT</b> be delivered to the patient at the same time with any medications intended for central nervous system administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Administer IV over 1 to 3 minutes into a free-flowing IV line. The preferred vinca alkaloid administration is as a short 5- to 10-minute infusion in a 25 to 50 mL minibag (ISMP 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase (see Management of Drug Extravasations for more details); remove needle/cannula; apply dry warm compresses for 20 minutes 4 times a day for 1 to 2 days; elevate extremity (ESMO/EONS [Perez Fidalgo 2012]). Remaining portion of the vindesine dose should be infused through a separate vein.</p></div>
<div class="block hazard drugH1Div" id="F49133466"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Vindesine is a cytotoxic drug (per product labeling).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016).</p></div>
<div class="block use drugH1Div" id="F45040074"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the US and/or Canada.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia, resistant:</b> Treatment of resistant childhood acute lymphoblastic leukemia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, advanced:</b> Treatment of advanced breast cancer unresponsive to appropriate endocrine surgery and/or hormonal therapy (if indicated).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic myeloid leukemia:</b> Treatment of blast crisis of chronic myeloid leukemia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, malignant:</b> Treatment of unresponsive malignant melanoma.</p></div>
<div class="block off-label drugH1Div" id="F25744937"><span class="drugH1">Use: Off-Label: Adult</span><p>Adult T-cell leukemia/lymphoma; Non-Hodgkin lymphoma (diffuse large B-cell)</p></div>
<div class="block mst drugH1Div" id="F3402926"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Vindesine may be confused with vinblastine, vincristine, vinorelbine.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">For IV use only. Fatal if administered by other routes. To prevent fatal inadvertent intrathecal injection, it is recommended by the World Health Organization (WHO) that vinca alkaloid doses be dispensed in a small minibag.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F29043845"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F29043842"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Vindesine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Vindesine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MitoMYcin (Systemic): Antineoplastic Agents (Vinca Alkaloids) may enhance the adverse/toxic effect of MitoMYcin (Systemic). Specifically, the risk of pulmonary toxicity may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: Vindesine may decrease the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53632825"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Patients who could become pregnant and patients with partners who could become pregnant should use effective contraception during vindesine treatment.</p></div>
<div class="block pri drugH1Div" id="F14081457"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on data from animal reproduction studies, in utero exposure to vindesine may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F14081458"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;">Use during breastfeeding is not recommended.</p></div>
<div class="block mop drugH1Div" id="F45040079"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential, LFTs. Monitor infusion site. Monitor for signs/symptoms of infection (particularly if granulocytes are &lt;1,000/mm<sup>3</sup>), neurotoxicity, pulmonary toxicity, and/or for constipation (including acute abdominal pain).</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F234260"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Vindesine is a semisynthetic vinca alkaloid derived from vinblastine; it binds to and stabilizes tubulin, thus disrupting the formation of the mitotic spindle and arresting the cell cycle at metaphase.</p></div>
<div class="block phk drugH1Div" id="F234270"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces; urine.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539953"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Eldisine</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Eldisin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Eldisine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Eldisine</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Eldisine</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai de xin | Nuo bei ke | Tuo ma ke | Xi ai ke</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Eldisine</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Eldisine | Gesidine</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Eldisine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Enison</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Eldisine</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Eldisine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Eldisine</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Eldisine | Gesidine</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Eldisine</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Fildesin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Eldisine</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Eldisine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Eldisine | Eldisine farma mondo</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Eldisine</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Eldisine</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Eldisin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Eldisine</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Eldisine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Eldisine (vindesine sulphate) [summary product characteristics]. Huddersfeild, UK: Genus Pharmaceuticals Limited; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vindesine-united-states-not-available-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vindesine-united-states-not-available-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Institute for Safe Medicine Practices (ISMP). ISMP targeted medication safety best practices for hospitals. https://www.ismp.org/sites/default/files/attachments/2020-02/2020-2021%20TMSBP-%20FINAL_1.pdf. Published February 21, 2020. Accessed January 14, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25385729">
<a name="25385729"></a>Molina TJ, Canioni D, Copie-Bergman C, et al. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B. <i>J Clin Oncol</i>. 2014;32(35):3996-4003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vindesine-united-states-not-available-drug-information/abstract-text/25385729/pubmed" id="25385729" target="_blank">25385729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27868581">
<a name="27868581"></a>Neuss MN, Gilmore TR, Belderson KM, et al. 2016 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards, including standards for pediatric oncology. <i>J Oncol Pract</i>. 2016;12(12):1262-1271. doi:10.1200/JOP.2016.017905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vindesine-united-states-not-available-drug-information/abstract-text/27868581/pubmed" id="27868581" target="_blank">27868581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. <i>Ann Oncol</i>. 2012;23 (Suppl 7):vii167-vii173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vindesine-united-states-not-available-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Polovich M, Whitford JN, Olsen M. <i>Chemotherapy and Biotherapy Guidelines and Recommendations for Practice</i>. 3rd ed. Oncology Nursing Society; 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22118442">
<a name="22118442"></a>Récher C, Coiffier B, Haioun C, et al; Groupe d'Etude des Lymphomes de l'Adulte. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. <i>Lancet</i>. 2011;378(9806):1858-1867.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vindesine-united-states-not-available-drug-information/abstract-text/22118442/pubmed" id="22118442" target="_blank">22118442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15788496">
<a name="15788496"></a>Reyes F, Lepage E, Ganem G, et al; Groupe d'Etude des Lymphomes de l'Adulte (GELA). ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. <i>N Engl J Med</i>. 2005;352(12):1197-1205.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vindesine-united-states-not-available-drug-information/abstract-text/15788496/pubmed" id="15788496" target="_blank">15788496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21255716">
<a name="21255716"></a>Schulmeister L. Extravasation management: clinical update. <i>Semin Oncol Nurs</i>. 2011;27(1):82-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vindesine-united-states-not-available-drug-information/abstract-text/21255716/pubmed" id="21255716" target="_blank">21255716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17968021">
<a name="17968021"></a>Tsukasaki K, Utsunomiya A, Fukuda H, et al; Japan Clinical Oncology Group Study JCOG9801. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. <i>J Clin Oncol</i>. 2007;25(34):5458-5464.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vindesine-united-states-not-available-drug-information/abstract-text/17968021/pubmed" id="17968021" target="_blank">17968021</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference">
                  World Health Organization. Vincristine (and Other Vinca Alkaloids) Should Only Be Given Intravenously via a Minibag. Alert 115, July 2007, World Health Organization, Geneva. http://www.who.int/medicines/publications/drugalerts/Alert_115_vincristine.pdf.</div>
</li></ol></div><div id="topicVersionRevision">Topic 10303 Version 153.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
